Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiang Li
Observed name:
X. Li
Institution:
Nanjing University of Chinese Medicine
Observed institution:
Nanjing University of Chinese Medicine
ORCID:
0000-0002-0441-9154
Observed ORCID:
0000-0002-0441-9154
OpenAlex ID:
A5138813721
CD146 + CAFs mediate immunosuppression in gastric cancer via COL4A1: potential therapeutic targets
2025
·
Jia Chen
, Peng Xu
, et al.
·
Journal for ImmunoTherapy of Cancer
·
8
Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
·
Cancer Research
·
5
Supp. Table S3 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Fig. S4 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Fig. S2 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Fig. S5 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Fig. S1 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Table S2 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Fig. S6 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Table S4 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Table S1 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Supp. Fig. S3 from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
Data from Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer
2026
·
Qingyuan Wang
, Peng Xu
, et al.
476TiP TREMENDOUS-2: An open-label, multi-center phase II study of durvalumab and tremelimumab with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma
2025
·
F. Shen
, C. Hao
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
14
Citation count:
13
H-index:
2
I10-index:
Year
Topic
Type